5 Ways Poor Glycemic Control Is Costing Your Hospital More Than You Think

Written by: JM2 Health Editorial Team · Medically reviewed by: Dr. Cheryl Fassler

Most hospital administrators and clinical leaders recognize inpatient hyperglycemia as a patient safety concern. What the data make unmistakably clear is that poor glycemic control is also an operational and financial challenge playing out across care settings every day.

Observational studies have reported hyperglycemia or diabetes in roughly 38–40% of hospitalized patients. Among hospitalized patients with diabetes who become critically ill or undergo cardiac surgery, reported hyperglycemia rates reach 70–80%. In 2020, more than one in three U.S. hospital discharges listed diabetes as a diagnosis.¹ These patients are not statistical outliers — they represent a substantial portion of your census on any given day.

For these patients, uncontrolled blood glucose is associated with longer stays, higher complication rates, reimbursement risk, heavier nursing workload, and a greater likelihood of a preventable 30-day readmission. This is not a clinical editorial. It is an operational reckoning. Here is where the costs accumulate — and what health systems are doing to reverse them.

1. Extended Length of Stay from Uncontrolled Blood Glucose

Extended length of stay (LOS) is one of the most direct and measurable consequences of inpatient hyperglycemia — and the cost impact is significant.

In cardiac surgery cohorts, higher perioperative glucose has been associated with longer stays. In a study of 1,574 CABG patients, each 50 mg/dL rise in perioperative glucose was associated with roughly a 0.76-day increase in postoperative LOS (95% CI 0.36–1.17) and about $2,824 in additional hospital charges per patient (95% CI $1,599–$4,049).² The same analysis reported approximately $1,769 in additional hospital cost — charges and cost are distinct metrics, and the distinction matters when modeling locally.

The Portland Diabetic Project followed 3,554 patients with diabetes undergoing coronary artery bypass grafting, comparing intermittent subcutaneous insulin against continuous intravenous insulin infusion. The infusion group achieved a mean glucose of 177 mg/dL versus 214 mg/dL, and recorded significantly fewer deep sternal wound infections alongside a 50% lower risk-adjusted mortality.^3,1

The pattern is not limited to cardiac surgery. A study of patients admitted with congestive heart failure found that persistent hyperglycemia (mean blood glucose ≥140 mg/dL) was associated with a mean LOS of 8.1 days, versus 5.2 days for those with controlled glucose — nearly three additional days per patient.⁴ Across hundreds or thousands of annual admissions, that difference translates directly into bed availability, staffing ratios, and throughput.

The mortality signal points the same direction, and it points hardest at the patients nobody labeled. In a study of 1,886 patients on general hospital floors, mortality was 10% among those with newly diagnosed hyperglycemia, versus 1.7% for patients with known diabetes and 0.8% for patients with normal glucose values (p < 0.01).¹ The patient whose hyperglycemia was never recognized fared worst — roughly six times the mortality of the patient whose diabetes was on the chart.

The Operational Implication
Hyperglycemia is consistently associated with prolonged stays, higher ICU admission rates, and greater need for post-discharge nursing care.¹ For a hospital with thousands of diabetes-related admissions each year, even a modest per-patient improvement frees meaningful bed-day capacity — though any dollar figure should be modeled using that hospital’s own census, payer mix, staffing, and cost-per-day assumptions.

2. Higher Rates of Surgical Complications, Infections, and Wound-Healing Failures

The relationship between elevated blood glucose and postoperative complications is physiologically direct and documented across multiple surgical specialties. Severe hyperglycemia impairs neutrophil granulocyte function, elevates circulating free fatty acids, and drives overproduction of pro-inflammatory cytokines and reactive oxygen species — producing direct cellular damage alongside endothelial and immune dysfunction.¹

A systematic review and meta-analysis in Infection Control & Hospital Epidemiology found that diabetes was associated with increased surgical site infection risk across surgical types, with an odds ratio of 1.53 (95% predictive interval 1.11–2.12). For cardiac surgery specifically, the association was stronger — an odds ratio of 2.03 (95% PI 1.13–4.05).⁶

The threshold matters, not just the diagnosis. A study of 2,090 general and vascular surgery patients published in Archives of Surgery (now JAMA Surgery) found a stark dose-response relationship between the first postoperative glucose value and surgical site infection:⁵

The finding that should command a surgical chief’s attention is what happened when the authors adjusted for postoperative glucose: every other risk factor stopped being significant. Age, emergency status, ASA class, operative time, diabetes itself — all of them ceased to predict infection once postoperative glucose entered the model. The authors concluded that postoperative hyperglycemia may be the single most important risk factor for SSI in general surgery patients. Among colorectal patients specifically, a postoperative glucose above 140 mg/dL was the only significant predictor, carrying 3.2 times the infection risk (95% CI 1.4–7.2).⁵

Two caveats a careful reader will want. The association did not hold for vascular surgery patients, where postoperative glucose was not associated with SSI.⁵ And association is not causation — it remains possible that accumulated risk factors produce hyperglycemia rather than the reverse.¹⁵

SSIs are not a soft cost. A peer-reviewed meta-analysis of healthcare-associated infection costs estimated the annual U.S. burden of surgical site infections at approximately $3.3 billion, among the costliest HAI categories.⁷ At the individual patient level, an SSI extends hospitalization and triggers additional imaging, laboratory work, wound-care consults, IV antibiotics, and sometimes a return to the operating room.

The Operational Implication
For a high-volume surgical program, even small reductions in SSI rates carry material operational and cost implications. A meta-analysis found that improving perioperative glycemic control reduced postoperative infection rates.¹ Poor glycemic control is a modifiable risk factor — and leaving it unmanaged is a choice with a measurable price tag.

3. CMS Quality-Measure Requirements and Reimbursement Risk Tied to Glycemic Metrics

The regulatory landscape shifted decisively in 2026. Beginning with the 2026 reporting period, CMS requires hospitals to report two electronic clinical quality measures (eCQMs) tied directly to glycemic management through the Hospital Inpatient Quality Reporting (IQR) Program:

• Hospital Harm — Severe Hypoglycemia (CMS816v5; CBE #3503e): among adult inpatients who received at least one hypoglycemic medication, the measure captures severe hypoglycemic events — a blood glucose result below 40 mg/dL after that medication exposure (a prompt repeat value above 80 mg/dL within five minutes removes point-of-care false positives).⁸
• Hospital Harm — Severe Hyperglycemia (CMS871v5; CBE #3533e): a ratio of qualifying adult inpatient hospital days with a severe hyperglycemic event — a day with a glucose value above 300 mg/dL, or an untested day bracketed by two consecutive days each with a glucose value at or above 200 mg/dL — over total eligible days, assessed across days 2 through 10 of the stay (the first 24 hours, and any final period shorter than 24 hours before discharge, are excluded).⁹

The Hospital IQR Program is pay-for-reporting. Hospitals that do not meet IQR reporting requirements are subject to a one-fourth reduction of their IPPS annual payment update — a cut to the yearly payment update, not to total Medicare reimbursement, but one that compounds across a hospital’s entire DRG payment base.¹⁰ These measures are also publicly reported, feeding the quality profile that increasingly shapes value-based contracting.

This is not a future problem. The 2026 reporting cycle has already begun, and health systems without the infrastructure to capture, analyze, and act on point-of-care glucose data at scale are already accumulating exposure. CMS frames these events as “hospital harms” — quality indicators that reflect the care delivered, not incidental clinical outcomes.

Readmissions add a separate layer of exposure. Under the Hospital Readmissions Reduction Program (HRRP), there is no diabetes-specific measure; rather, excess readmissions within the program’s six defined condition and procedure cohorts — heart attack, heart failure, pneumonia, COPD, CABG, and elective hip/knee replacement — can reduce a hospital’s Medicare base operating DRG payments by up to 3%.¹¹ Diabetes is not among the six, but it travels with them: patients with diabetes are disproportionately represented in exactly those cohorts.

The Operational Implication
Glycemic management is no longer a clinical-quality project confined to the endocrinology department. It is a finance and compliance issue that belongs on the CFO’s dashboard and the CMO’s quarterly review agenda.

4. Nursing and Staff Burden from Manual Insulin Management and Protocol Inconsistency

For bedside nurses, insulin management is one of the most time-intensive, cognitively demanding, and error-prone components of inpatient care. In most hospitals it remains largely manual, inconsistently executed, and inadequately supported.

Time-in-motion research across a range of intensive care units found that tight glycemic control can require up to two hours per patient over a 24-hour period for blood glucose monitoring and insulin-adjustment tasks. The authors’ conclusion was blunt: although most nurses endorse tight glycemic control, the work associated with it is burdensome and costly, and easier clinical methods are needed.¹² Where a single nurse manages two patients on insulin infusions, monitoring alone can consume a substantial share of the shift.

This is not a personnel failure; it is a systems failure. When nurses must simultaneously manage meal-delivery timing, physician order sets, infusion titration, and documentation — without structured decision support — protocol deviations are the predictable outcome. And the evidence is consistent that no insulin algorithm succeeds without close nursing follow-up, and that manual protocols are prone to human error; some institutions have moved to computerized protocols specifically to avoid dosing errors.¹

The consequences are clinical and financial, and they run in both directions. Protocol deviations produce glucose excursions — but overcorrection produces hypoglycemia, which carries its own well-documented cost. In an analysis of 4,368 admission episodes, patients who experienced inpatient hypoglycemia had a 66% increased risk of death within one year and spent 2.8 days longer in the hospital than those who did not.¹ A 2019 systematic review and meta-analysis of hospital-acquired hypoglycemia in non-ICU patients found a mean increased length of stay of 4.1 days (95% CI 2.36–5.79) and a relative risk of in-hospital mortality of 2.09 (95% CI 1.64–2.67).¹

A common and entirely preventable cause of inpatient hypoglycemia is the handwritten insulin prescription — misreading “4U” as 40 units, or confusing an insulin name with its dose. Electronic prescribing is associated with a lower rate of prescription errors.¹

The Operational Implication
Standardized, evidence-based glycemic protocols supported by clinical decision support don’t just improve patient outcomes — they reclaim nursing time, reduce protocol-deviation rates, and lower the per-patient cost of insulin management.

5. Preventable Readmissions from Poor Discharge Planning and Lack of Outpatient Follow-Up

Readmission is where the care gap becomes a billing event. Among individuals with a discharge diagnosis of diabetes, 30% will require two or more hospitalizations in any given year.¹ These are not random clinical events. They are the predictable downstream consequence of a gap that opens the moment the discharge order is written.

Formal inpatient diabetes education has been associated with a 34% lower adjusted odds of 30-day readmission in observational data — an 11% readmission rate among educated patients versus 16% among those who received no education.¹³

The structural fix shows similar results. In a retrospective analysis at a 240-bed community hospital, mean 30-day readmission rates fell from 25% to 14.29% after a structured inpatient diabetes management service was implemented — a 10.71-percentage-point reduction in that setting, achieved by a team consisting of an endocrinologist, a nurse practitioner, and a diabetes educator.¹⁴ That is a single-center retrospective result, not a randomized trial, and it should be read as a signal rather than a guarantee.

The financial exposure is significant. Each readmission carries direct Medicare cost, HRRP penalty risk, and reputational risk in value-based contracting.

The Operational Implication
Discharge planning for patients with diabetes cannot be a checkbox activity. Structured transitions — medication reconciliation, glucose-target communication, primary-care follow-up scheduling, and self-management education — are not optional enhancements. They are interventions with published evidence of reduced readmissions and cost exposure in some settings.

The Path Forward: A Systems-Level Solution

The five cost drivers above share a common root cause: the absence of a standardized, systematically delivered approach to inpatient glycemic management. When glucose management is distributed across primary teams without specialized oversight, evidence-based protocols, or structured transitions of care, variability is the inevitable result — and variability is expensive.

Health systems working to reverse these trends tend to share a common structural approach. They build or contract specialized inpatient glycemic management programs that integrate three components:

• Specialized glycemic-management clinicians — advanced practice providers (APPs) and diabetes-focused clinical staff — who provide real-time consultation and protocol oversight.
• Evidence-based, standardized insulin management protocols embedded directly into clinical workflows, reducing decision burden and the protocol deviations that drive glucose excursions and nursing overtime.
• Clinical decision support and software-guided insulin-dosing tools that automate glucose-monitoring alerts, flag at-risk patients, and generate the structured data required for CMS eCQM reporting.

The economics have been measured. In the GLUCO-CABG randomized trial, intensive glucose management produced a 20% reduction in perioperative complications versus conservative control (42% vs. 52%) — and hospitalization costs were lower in the intensive group, with an average total cost saving of $3,654 per case.¹ In a randomized study of 1,371 surgical inpatients, early intervention by a diabetes inpatient team for patients with even a single glucose value above 200 mg/dL produced a statistically significant 4.6% reduction in hospital-acquired infections.¹ And in general surgery patients, a basal-bolus regimen reduced average total inpatient costs per day by 14%, or $751, compared with correction-dose insulin alone.¹

It is worth being precise about what the evidence does and does not establish. The large ICU trials of tight glycemic control — NICE-SUGAR among them — did not show mortality benefit and did show increased hypoglycemia.¹ The case for structured glycemic management is not a case for aggressive glucose targets. It is a case for consistency, identification, and avoiding both extremes.

For hospital administrators, CMOs, and CNOs navigating resource constraints and margin pressure, the calculus is straightforward: the cost of not acting is already embedded in your current performance data. The question is whether your organization treats inpatient glycemic management as a clinical support function or as a strategic operational priority. The hospitals that treat it as a priority are the ones best positioned to protect both outcomes and revenue.

This article is intended as thought leadership for hospital and health-system decision-makers and is not clinical guidance.

Sources

1. Dhatariya K, Umpierrez GE. Management of Diabetes and Hyperglycemia in Hospitalized Patients. In: Feingold KR, et al., eds. Endotext [Internet]. MDText.com; updated October 20, 2024. NBK279093. https://www.ncbi.nlm.nih.gov/books/NBK279093/ (free full text)
2. Estrada CA, Young JA, Nifong LW, Chitwood WR Jr. Outcomes and perioperative hyperglycemia in patients with or without diabetes mellitus undergoing coronary artery bypass grafting. Ann Thorac Surg. 2003;75(5):1392–1399. PMID 12735552. https://doi.org/10.1016/S0003-4975(02)04997-4
3. Furnary AP, Gao G, Grunkemeier GL, et al. Continuous insulin infusion reduces mortality in patients with diabetes undergoing coronary artery bypass grafting. J Thorac Cardiovasc Surg. 2003;125(5):1007–1021. PMID 12771873. https://doi.org/10.1067/mtc.2003.181
4. Hammer MJ, et al. Hyperglycemia is associated with increased length of stay and total cost in patients hospitalized for congestive heart failure. Open J Nurs. 2013;3:403–409. https://doi.org/10.4236/ojn.2013.35054 (free full text)
5. Ata A, Lee J, Bestle SL, Desemone J, Stain SC. Postoperative hyperglycemia and surgical site infection in general surgery patients. Arch Surg. 2010;145(9):858–864. https://doi.org/10.1001/archsurg.2010.179 (free full text)
6. Martin ET, Kaye KS, Knott C, et al. Diabetes and risk of surgical site infection: a systematic review and meta-analysis. Infect Control Hosp Epidemiol. 2016;37(1):88–99. PMID 26503187. https://doi.org/10.1017/ice.2015.249
7. Zimlichman E, Henderson D, Tamir O, et al. Health care–associated infections: a meta-analysis of costs and financial impact on the US health care system. JAMA Intern Med. 2013;173(22):2039–2046. PMID 23999949. https://doi.org/10.1001/jamainternmed.2013.9763
8. CMS. Hospital Harm — Severe Hypoglycemia (CMS816v5; CBE #3503e), 2026 reporting period. eCQI Resource Center. https://ecqi.healthit.gov/ecqm/hosp-inpt/2026/cms0816v5
9. CMS. Hospital Harm — Severe Hyperglycemia (CMS871v5; CBE #3533e), 2026 reporting period. eCQI Resource Center. https://ecqi.healthit.gov/ecqm/hosp-inpt/2026/cms0871v5
10. CMS. Hospital Inpatient Quality Reporting (IQR) Program; FY2026 IPPS/LTCH PPS Final Rule (CMS-1813-F), Federal Register Vol. 90, No. 148, August 5, 2025. https://www.cms.gov/medicare/payment/prospective-payment-systems/acute-inpatient-pps/fy-2026-ipps-final-rule-home-page
11. CMS. Hospital Readmissions Reduction Program (HRRP). https://www.cms.gov/medicare/payment/prospective-payment-systems/acute-inpatient-pps/hospital-readmissions-reduction-program-hrrp
12. Aragon D. Evaluation of nursing work effort and perceptions about blood glucose testing in tight glycemic control. Am J Crit Care. 2006;15(4):370–377. PMID 16823014. https://doi.org/10.4037/ajcc2006.15.4.370
13. Healy SJ, Black D, Harris C, Lorenz A, Dungan KM. Inpatient diabetes education is associated with less frequent hospital readmission among patients with poor glycemic control. Diabetes Care. 2013;36(10):2960–2967. PMID 23835695. https://pubmed.ncbi.nlm.nih.gov/23835695/
14. Mandel SR, Langan S, Mathioudakis NN, et al. Retrospective study of inpatient diabetes management service, length of stay and 30-day readmission rate of patients with diabetes at a community hospital. J Community Hosp Intern Med Perspect. 2019;9(2):64–73. PMID 31044034. https://pmc.ncbi.nlm.nih.gov/articles/PMC6484466/ (free full text)
15. American Diabetes Association Professional Practice Committee. 16. Diabetes Care in the Hospital: Standards of Care in Diabetes—2026. Diabetes Care. 2026;49(Suppl 1). https://doi.org/10.2337/dc26-S016 (free full text)